Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615000623594
Ethics application status
Approved
Date submitted
16/01/2015
Date registered
16/06/2015
Date last updated
8/06/2021
Date data sharing statement initially provided
8/06/2021
Date results provided
8/06/2021
Type of registration
Retrospectively registered

Titles & IDs
Public title
A multi-centre prospective observational study of simultaneous pulse oximeter and arterial oxygen saturation recordings in Intensive Care Unit patients.
Scientific title
In Intensive Care Unit patients requiring an arterial blood gas, a comparison between arterial oxygen saturation and pulse oximetry saturation measurements.
Secondary ID [1] 285878 0
Nil
Universal Trial Number (UTN)
U1111-1165-3894
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Any condition requiring measurement of arterial blood gas in the Intensive Care Unit 293799 0
Condition category
Condition code
Respiratory 294102 294102 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Evaluation of simultaneous pulse oximetry (SpO2) and arterial blood gas (ABG) measured oxygen saturation (SaO2) values recorded in ICU patients.

The paired SpO2 value will be recorded at least 2 hours after admission to ICU, to allow for adjustments in oxygen therapy to become in-line with standard ICU practice for oxygen administration. Where possible, paired measurements will be done during the earliest arterial blood gas (ABG) taken after at least 2 hours of admission.

A single set of paired measurements will be taken per patient.
Intervention code [1] 290859 0
Not applicable
Comparator / control treatment
The SpO2 value recorded by the pulse oximeter will be paired with the ABG measured oxygen saturation (SaO2) value for comparison.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 293894 0
SpO2, measured by pulse oximetry at the same time an ABG is performed.
Timepoint [1] 293894 0
The SpO2 value will be the first value displayed by the pulse oximeter following visualisation of blood entering the collection vial for the ABG analysis.
Primary outcome [2] 293895 0
SaO2, measured by ABG (while the pulse oximeter is in place).
ABG is assessed by means of a blood sample taken from an artery.
Timepoint [2] 293895 0
Taken at time of the clinically indicated ABG.
Secondary outcome [1] 312105 0
Nil
Timepoint [1] 312105 0
Nil

Eligibility
Key inclusion criteria
Four hundred patients with routine oxygen saturation monitoring and routine ABG measurements as part of their clinical care at Wellington Regional Hospital and Austin Hospital ICUs.
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Diagnosis of methaemoglobinemia or prior use of intravenous dye during this admission(e.g. methylene blue).
2. Diagnosis of CO poisoning.
3. Age under 16 years.
4. Patients previously recruited to the study with paired SpO2 and SaO2 values successfully recorded.
5. Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact upon the feasibility of the study or the interpretation of the study results.

Study design
Purpose
Natural history
Duration
Cross-sectional
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
STUDY OBJECTIVES:

1. To describe the agreement between paired SpO2 and SaO2 measurements in terms of bias and limits of agreement.
2. To estimate the influence on bias of the paired SpO2 and SaO2 measurements by:
a. The mean oxygen saturation (average of SpO2 and SaO2)
b. PaCO2
c. APACHE II score (> 25 vs <25)
d. Inotrope administration at the time of ABG sample (yes or no)
e. Vasopressor administration at the time of ABG sample (yes or no)
f. Values immediately prior to ABG sample:
i. Capillary refill (<3 seconds vs >3 seconds)
ii. Last recorded axillary body temperature
iii. Temperature of hands (warm vs cool to touch)
iv. Mean arterial blood pressure
v. Pulse pressure
vi. Identification of any local factor by the nursing staff as potentially impacting on oximetry probe recording (e.g. motion artefact)
g. Skin pigmentation (based on modified Fitzpatrick scale with patient skin colour classified as either: Light (Type I to Type II), Medium (Type III to Type IV) or Dark (Type V to Type VI))
h. Pulse oximeter model (Philips IntelliVue MP70 or Mossimo TRAM-RAC 4A)
3. To describe the diagnostic performance of SpO2 to detect clinically important boundaries of SaO2 (90 %) and arterial oxygen tension (PaO2) (60 mmHg).

STATISTICAL METHODS:
Objective 1: Bland-Altman plots and estimation of bias and limits of agreement.
Objective 2: Analysis of Covariance. Should important predictors of bias be identified Bland-Altman methods will be used to determine whether there is also an effect on limits of agreement.
Objective 3: Receiver Operating Characteristic curve estimation by logistic regression and associated prediction equations.


SAMPLE SIZE:
The planned sample size is based on three considerations. Firstly, for the analysis of variables that predict the size of the bias we seek to have between 20 and 40 participants for each degree of freedom in the ANCOVA. Based on the thirteen variables, some of which have multiple levels, this requires between 200 and 400 participants. Secondly, the estimates of paired SD for the SpO2 to SaO2 difference from the papers of Pu, Van de Leow and Wouters; were 0.55%, 2.1%, and 2.2% respectively. We wish to detect a SpO2 to SaO2 difference of 2% for any of the variables that might predict bias. If there were two equal sized groups of 42 participants, 21 in each group, there is 80% power, with a type I error rate of 5%, to detect this size difference. This suggests that a minimum of 20 participants with a particular characteristic will provide greater than 80% power to detect a difference of 2% between groups for dichotomous variables (because the complement of a particular characteristic will have be more numerous than 20). We consider a sample size of 400 as being likely that each individual characteristic will have at least 20 participants.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
10/06/2015
Actual
10/06/2015
Date of last participant enrolment
Anticipated
Actual
26/04/2016
Date of last data collection
Anticipated
Actual
27/04/2016
Sample size
Target
400
Accrual to date
Final
400
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 3291 0
Austin Health - Austin Hospital - Heidelberg
Recruitment outside Australia
Country [1] 6560 0
New Zealand
State/province [1] 6560 0
Wellington

Funding & Sponsors
Funding source category [1] 290460 0
Charities/Societies/Foundations
Name [1] 290460 0
Medical Research Institute of New Zealand
Country [1] 290460 0
New Zealand
Primary sponsor type
Charities/Societies/Foundations
Name
MRINZ
Address
MRINZ,
Wellington Regional Hospital,
Riddiford Street,
Newtown,
Wellington 6021
Country
New Zealand
Secondary sponsor category [1] 289162 0
None
Name [1] 289162 0
Nil
Address [1] 289162 0
Nil
Country [1] 289162 0
Other collaborator category [1] 278271 0
Individual
Name [1] 278271 0
Dr Michael Richards
Address [1] 278271 0
MRINZ,
Wellington Regional Hospital,
Riddiford Street,
Newtown,
Wellington 6021
Country [1] 278271 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 292133 0
Northern A Health and Disability Ethics Committee
Ethics committee address [1] 292133 0
Ethics committee country [1] 292133 0
New Zealand
Date submitted for ethics approval [1] 292133 0
24/10/2014
Approval date [1] 292133 0
15/12/2014
Ethics approval number [1] 292133 0
14/NTA/180

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 53666 0
Dr Janine Pilcher
Address 53666 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country 53666 0
New Zealand
Phone 53666 0
+64 4 8050241
Fax 53666 0
+64 4 3895707
Email 53666 0
[email protected]
Contact person for public queries
Name 53667 0
Janine Pilcher
Address 53667 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country 53667 0
New Zealand
Phone 53667 0
+64 4 8050241
Fax 53667 0
+64 4 3895707
Email 53667 0
[email protected]
Contact person for scientific queries
Name 53668 0
Janine Pilcher
Address 53668 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country 53668 0
New Zealand
Phone 53668 0
+64 4 8050241
Fax 53668 0
+64 4 3895707
Email 53668 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.